Supplemental Online Content

Dedhia PH, Saucke MC, Long KL, Doherty GM, Pitt SC. Physician perspectives of overdiagnosis and overtreatment of low-risk papillary thyroid cancer in the US. *JAMA Netw Open*. 2022;5(4):e228722. doi:10.1001/jamanetworkopen.2022.8722

eAppendix. National Study of Providers' Practices for Thyroid Cancer

This supplemental material has been provided by the authors to give readers additional information about their work.



Wisconsin Surgical Outcomes Research Program

Department of Surgery
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

National Study of Providers' Practices for Thyroid Cancer

You can skip any questions that you do not want to answer. Please also feel free to write any additional comments you may have. For the purposes of this survey, *active surveillance* refers to performing serial physical exams, ultrasounds, and/or laboratory tests on a patient with biopsy-proven thyroid cancer, but who is <u>not</u> undergoing surgery at this time, also called "watchful waiting."

1. The first several questions are about your practice.
Which of the following <u>best</u> describes your specialty?
○ Endocrinology
○ General surgery
Otolaryngology
Other → Please tell us:
2. Does your current practice include a focus on thyroid disease?
○Yes
ONo
3. Since December 2015, have you cared for any patients with thyroid nodules or thyroid cancer?
⊢ ○Yes
○No → Go to question 29
4. In the last 12 months, about how many <u>new or established</u> patients with <u>thyroid cancer</u> have you cared for?
○5 or fewer
○6 to 10
O11 to 25
\bigcirc 26 to 50
OMore than 50
Onlore diam 50
If you are a surgeon
If you are not a surgeon Go to question 7

5. In a 12 month period, about how many thyroid surgeries do you typically perform?

© 2022 Dedhia PH et al. JAMA Network Open.

	thyroid surgeries						
6.	6. Who <u>primarily</u> performs FNA on your patients with thyroid nodules?						
	 ○Myself ○Surgeon ○Endocrinologist ○Radiologist Other → Please tell us: 						
	Other I lease tell us.						
7.	7. At what size do you recommend FNA of a thyroid nodule with features concerning for papillary thyroid cancer, such as microcalcifications, irregular borders, and increased vascularity? Centimeters (1 cm = 10 mm) or larger						
	Continuetors (1 cm	10 mm) of larger					
8.	8. At what size do you recommend FNA of a thyroid nodule without any concerning features?						
	Centimeters (1 cm =	= 10 mm) or larger					
9.	The next questions are about 1	management of <u>low-ri</u>	sk thyroid cance	r and factors	that may		
	influence your recommendation	ons.					
For this question, consider a healthy <u>45-year old</u> female patient with a <u>biopsy-proven</u> , <u>solitary</u> papillary thyroid cancer. In addition, assume she has: • <u>No</u> contralateral nodules • <u>No</u> lymphadenopathy • <u>No</u> extrathyroidal extension • <u>No</u> family history of thyroid cancer or history of head and neck radiation							
	For each of the following scenarios, please indicate which management option you would recommend if you could recommend <u>only one</u> approach.						
	Would you recommend total thyroidectomy with central neck dissection, total thyroidectomy, thyroid lobectomy, or active surveillance for a cancer that is						
		Total thyroidectomy with central neck dissection	Total thyroidectomy	Thyroid lobectomy	Active surveillance		
	a. 0.8 cm?	0	0	0	0		
	b. 0.8 cm and patient prefers total thyroidectomy?	0	0	0	0		

risk thyroid cancer.						
How much influence does each of the following factors have on your decision?						
	None	A little	Some	Quite a bit	A gre deal	
a. Clinical characteristics, such as size of the cancer or patient age	\circ	0	0	0	0	
b. Risks of complications	0	0	0	0	0	
c. Risk of cancer recurrence	\circ	0	0	\circ	0	
d. Ease of follow-up	0	0	0	0	0	
e. Patient reliability to follow-up	\circ	\circ	\circ	\circ	\circ	
f. Peace of mind from more extensive surgery	0	0	0	0	0	
g. Need for life-long thyroid hormone replacement	0	0	0	0	0	
h. Recommendation of referring provider	0	0	0	0	0	
i. Patient preference	0	0	0	0	0	
j. Concern about doing less extensive surgery	0	0	0	0	0	
and were found to have a low-risk papillar For whom do you recommend a completio For all patients For most patients	y thyroid	cancer on fi			te nodu	
and were found to have a low-risk papillar For whom do you recommend a completion For all patients For most patients For select patients Only for patients who have an incidental patients For no patients Think about your decision whether to recommend.	y thyroid on thyroide ositive lym	cancer on fire ctomy?	nal patholo	ogy		
For whom do you recommend a completion For all patients For most patients For select patients Only for patients who have an incidental property of the patients Think about your decision whether to recommend a low-risk papillary thyroid cancer.	y thyroid on thyroide ositive lym	ctomy? aph node on the completion	final patholothy	ogy omy for a p		
and were found to have a low-risk papillar For whom do you recommend a completion For all patients For most patients Only for patients who have an incidental patients For no patients Think about your decision whether to recommend.	y thyroid on thyroide ositive lym	ctomy? aph node on the completion	final patholothy	ogy omy for a p		
and were found to have a low-risk papillar For whom do you recommend a completion For all patients For most patients Only for patients who have an incidental property of the patients Think about your decision whether to recommend a low-risk papillary thyroid cancer.	y thyroid on thyroide ositive lymemend a gwing factor	cancer on fine ctomy? The ph node on the completion of the comple	final pathol thyroidecto	ogy omy for a p on? Quite a	atient v	
For whom do you recommend a completion For all patients For most patients For select patients Only for patients who have an incidental propertients Think about your decision whether to recommend a low-risk papillary thyroid cancer. How much influence does each of the following.	ositive lym mmend a	cancer on fine ctomy? The ph node on the completion of the comple	final pathol thyroidect our decisio	ogy omy for a p on? Quite a bit	atient v	
and were found to have a low-risk papillar For whom do you recommend a completion For all patients For most patients Only for patients who have an incidental patients To no patients Think about your decision whether to recommend a low-risk papillary thyroid cancer. How much influence does each of the following a. Clinical characteristics, such as size of the cancer or multifocality b. Ability to perform radioactive iodine	ositive lymemmend a grade wing factor	cancer on fine ctomy? The ph node on the completion of the comple	final patholothyroidectoric Some	ogy omy for a p on? Quite a bit	A gre	
and were found to have a low-risk papillar For whom do you recommend a completion For all patients For most patients Only for patients who have an incidental property For no patients Think about your decision whether to recommend a low-risk papillary thyroid cancer. How much influence does each of the following a Clinical characteristics, such as size of the cancer or multifocality	ositive lym mmend a wing factor	cancer on fine ctomy? The ph node on the completion of the comple	final pathological	ogy omy for a p on? Quite a bit	A gre	
and were found to have a low-risk papillar For whom do you recommend a completion For all patients For most patients Only for patients who have an incidental property For no patients Think about your decision whether to recommend a low-risk papillary thyroid cancer. How much influence does each of the following the cancer or multifocality a. Clinical characteristics, such as size of the cancer or multifocality b. Ability to perform radioactive iodine c. Ability to follow thyroglobulin d. Need for life-long thyroid hormone	ositive lym mmend a wing factor	cancer on fine ctomy? The ph node on the completion of the comple	final patholo thyroidecto our decisio	ogy omy for a p on? Quite a bit	A gre	
And were found to have a low-risk papillar For whom do you recommend a completion For all patients For most patients Only for patients who have an incidental position of patients Think about your decision whether to recommend a low-risk papillary thyroid cancer. How much influence does each of the following the cancer or multifocality b. Ability to perform radioactive iodine c. Ability to follow thyroglobulin d. Need for life-long thyroid hormone replacement	ositive lym mmend a wing factor None	cancer on fine ctomy? The ph node on the completion of the comple	final patholo thyroidecto our decisio	ogy omy for a p on? Quite a bit	A gredeal	

13.	13. I nink about patients with <u>low-risk</u> papillary thyroid cancer.						
	For whom do you recommend central neck dissection?						
	 For all patients For most patients For select patients Only for patients who have clinically positive lymph nodes on ultrasound or discovered intraoperatively For no patients 						
1.4	Think about nationts with law risk nanillar	my thymaid	concer For	whom do r	ZOIL MOGOMI	mond DAI2	
14. Think about patients with low-risk papillary thyroid cancer. For whom do you recommend RAI? OFor all patients OFor most patients OFor select patients Only for patients who have positive lymph nodes on final pathology OFor no patients							
15. Think about your decision whether to recommend RAI for a patient with low-risk thyroid cancer. How much influence does each of the following factors have on your decision?							
					Quite a	A great	
		None	A little	Some	bit	deal	
	a. Clinical characteristics, such as size of the cancer or patient age	0	0	0	0	0	
	b. Risk of side effects	0	0	0	0	0	
	c. Risk of cancer recurrence	0	0	0	0	0	
	d. Patient reliability to follow-up	0	0	0	0	0	
	e. Peace of mind from treatment with RAI	0	O	0	0	<u> </u>	
	f. Recommendation of other clinician	0	0	0	0	0	
	g. Patient preference to not receive RAI	0	0	0	0	0	
	h. Concern about not giving RAI	0	0	0	0	0	
16. In <u>your</u> opinion, is each of the following treatments for <u>low-risk</u> thyroid cancer overused, appropriately used, or underused in the United States?							
			Overused	Appropi use	-	nderused	
	a. Radioactive iodine		0	0		0	
	b. Total thyroidectomy with central neck disse	ection	0	0		0	
	c. Total thyroidectomy alone		0	0		0	
	d. Thyroid lobectomy		0	0		0	
	e. Active surveillance		0	O		0	
17.	17. Finally, we have a few questions about you and your practice. How many years have you practiced, since you finished your training?						

18. What is your age? years						
19. Which of the following describes how you think of yourself?						
Female						
○ Male						
○In another way: Please tell us: →						
20. Which of the following best describe your race or ethnicity? (I	Please cl	neck all that app	oly)			
○American Indian or Alaskan Native						
OAsian						
OBlack or African American						
○Hispanic or Latino○Native Hawaiian or Other Pacific Islander						
White						
Other: Please tell us: →						
21. Which one of the following best describes the setting in which	you pra	ctice?				
○Academic tertiary hospital						
○ Academic-affiliated hospital						
Community hospital						
OPrivate practice						
○Other setting → Please tell us:						
22. In your practice, do you						
			Not			
	Yes	No	applicable			
a. have access to a tumor board to discuss your patients?	0	0	0			
b. personally perform thyroid ultrasounds on your patients?	0	0	0			
c. ever refer your patients to a high-volume thyroid surgeon?	0	0	0			
23. Do you use the following clinical guidelines in your practice?						
23. Do you use the following chinear guidelines in your practice.		Yes	No			
a. American Thyroid Association 2015		0	0			
b. American Association of Clinical Endocrinologists 2016		Ö	Ö			
c. National Comprehensive Cancer Network 2017		O				
d. Other guidelines? → Please tell us:						
24. What is the zip code where your practice is located?		5-digit	zip code			

Thank you for participating in this survey! Please return the questionnaire in the postage-paid envelope provided.